^
BIOMARKER:

ER mutation

i
Other names: ESR1, Era, ESR, NR3A1, ER, ER beta
Entrez ID:
ER mutation
Estrogen Receptor Positive Breast Cancer
palbociclib
Sensitive: B - Late Trials
ER mutation
Breast Cancer
palbociclib
Resistant: B - Late Trials
ER mutation
Hormone Receptor Positive Breast Cancer
exemestane
Resistant: B - Late Trials
ER mutation
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive: B - Late Trials
ER mutation
Estrogen Receptor Positive Breast Cancer
exemestane
Resistant: B - Late Trials
ER mutation
Hormone Receptor Positive Breast Cancer
fulvestrant
Sensitive: B - Late Trials
ER mutation
HER2 Negative Breast Cancer
Aromatase inhibitor + palbociclib
Resistant: B - Late Trials
ER mutation
Breast Cancer
fulvestrant
Sensitive: C2 – Inclusion Criteria
ER mutation
HER2 Negative Breast Cancer
GDC-9545
Sensitive: C2 – Inclusion Criteria
ER mutation
HER2 Negative Breast Cancer
palbociclib + PF-05212384
Sensitive: C3 – Early Trials
ER mutation
Breast Cancer
venetoclax
Sensitive: C3 – Early Trials
ER mutation
Estrogen Receptor Positive Breast Cancer
enobosarm
Sensitive: C3 – Early Trials
ER mutation
HER2 Negative Breast Cancer
SAR439859
Sensitive: C3 – Early Trials
ER mutation
HER2 Negative Breast Cancer
CDK6 inhibitor
Resistant: C3 – Early Trials
ER mutation
HER2 Negative Breast Cancer
CDK4 inhibitor
Resistant: C3 – Early Trials
ER mutation
Hormone Receptor Positive Breast Cancer
alpelisib
Resistant: C3 – Early Trials
ER mutation
HER2 Negative Breast Cancer
RAD1901
Sensitive: C3 – Early Trials
ER mutation
Estrogen Receptor Positive Breast Cancer
bevacizumab + paclitaxel
Sensitive: C3 – Early Trials
ER mutation
HER2 Negative Breast Cancer
G1T48
Sensitive: C4 – Case Studies
ER mutation
Estrogen Receptor Positive Breast Cancer
RAD1901
Sensitive: D – Preclinical